THE GREENS/EFA in the European Parliament

NOTRE BON DROIT EUROPE

"European Digital Covid Certificate: assessment and prospects"

Wednesday 20 April, 2022 - 1.00 pm - 3.00 pm

Assessment of the implementation of the EU Digital COVID Certificate

Alberto Donzelli, MD
Specialist in Hygiene&Preventive Medicine and Nutrition Science.
Former Senior Manager in Public Health and member of the Superior Health Council.
Board of Directors of *Allineare Sanità&Salute* Foundation

Conflict of interests: none, verify us! www.fondazioneallinearesanitaesalute.org

From 1 February 2022, new rules in the European Union establish **a binding acceptance period of <u>9 months for vaccination certificates</u>** for travel within the EU.
Member States must accept vaccination certificates for 9 months from the the last dose of the primary vaccination.

Are these rules able to prevent or drastically reduce a SARS-CoV-2 infection (and transmission to *others*)?

The Italian Law obliges health care and school workers, other professional categories and over-50s to receive vaccines and boosters "***<u>for the prevention of</u> SARS-CoV-2 <u>infection</u>***".

Unfortunately, there is strong scientific evidence that this prevention is impossible with current vaccines.

Indeed, in the medium term such vaccinations not only lose any protective effect, but involve **even greater infection risks**.

Time allows me only to focus on this problem, not on some useful alternatives.

Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study

BMJ 2022;376:e069052

with **Delta**

Massimo Fabiani,[1] Maria Puopolo,[1] Cristina Morciano,[1] Matteo Spuri,[1] Stefania Spila Alegiani,[1] ...
Silvio Brusaferro,[1] Giovanni Rezza,[2] Francesca Menniti Ippolito,[1] Patrizio Pezzotti,[1] on behalf



Fig 3 | Effectiveness of mRNA vaccines against SARS-CoV-2 infection during the delta phase by age group and priority risk category, Italy, 19 July to 7 November 2021. Vaccine effectiveness calculated as (1−IRR)×100, where IRR=incidence rate ratio. *Including people with comorbidities, immunocompromised people, and residents of long term care facilities

Including people with comorbidities, residents of long term care facilities, Immunocompromised people…

The ISS knew this since 2021…!



Fig 3 | Effectiveness of mRNA vaccines against SARS-CoV-2 infection during the delta phase by age group and priority risk category, Italy, 19 July to 7 November 2021. Vaccine effectiveness calculated as (1−IRR)×100, where IRR=incidence rate ratio. *Including people with comorbidities, immunocompromised people, and residents of long term care facilities

… This phenomenon is evident in subsequent publications of the Covid-19 vaccine surveillance report, Week 36 **Week 36**:

UK Health Security Agency

COVID-19 vaccine surveillance report Week 36

COVID-19 vaccine surveillance report – week 36

Table 4. COVID-19 cases by vaccination status between week 32 and week 35 2021

Cases reported by week of specimen date between week 32 and week 35 2021	Total	Unlinked*	Not vaccinated	Received one dose (1-20 days before specimen date)	Received one dose, ≥21 days before specimen date	Second dose ≥14 days before specimen date	Rates among persons vaccinated with 2 doses (per 100,000)	Rates among persons not vaccinated (per 100,000)
Under 18	167,832	15,901	141,676	8,132	1,366	757	476.0	1,192.9
18-29	176,392	19,529	53,187	4,598	66,545	32,533	711.1	1,520.8
30-39	113,373	12,452	33,986	1,497	22,434	43,004	782.2	1,143.9
40-49	97,881	8,930	15,106	496	6,000	67,349	1,116.2	880.4
50-59	84,488	6,868	7,552	168	2,248	67,65[illegible]	962.0	729.7
60-69	45,252	3,657	2,650	54	772	38,1[illegible]	672.3	487.5
70-79	25,499	2,034	910	12	273	22,270	480.5	367.5
80+	12,011	1,124	545	9	246	10,087	391.1	427.4

+766

cases in vaccinated still -17,2%

From week 36 (and subsequent), **in age classes 40-49 to 70-79 years, rates of COVID-19 cases among persons vaccinated (per 100.000) were greater** than rates among persons not vaccinated: **+766 cases**. But, comparing the entire columns, the vaccinated rates remained lower…

Week 43 - 2021

Table 5. Unadjusted rates of COVID-19 infection, hospitalisation and death in vaccinated and unvaccinated populations.

	Cases reported by specimen date between week 39 and week 42 2021		Cases presenting to emergency care (within 28 days of a positive test) resulting in overnight inpatient admission, by specimen date between week 39 and week 42 2021		Death within 28 days of positive COVID-19 test by date of death between week 39 and week 42 2021		Death within 60 days of positive COVID-19 test by date of death between week 39 and week 42 2021	
	Unadjusted rates among persons vaccinated with 2 doses (per 100,000)[1,2]	Unadjusted rates among persons not vaccinated (per 100,000)[1,2]	Unadjusted rates among persons vaccinated with 2 doses (per 100,000)[2]	Unadjusted rates among persons not vaccinated (per 100,000)[2]	Unadjusted rates among persons vaccinated with 2 doses (per 100,000)[2]	Unadjusted rates among persons not vaccinated (per 100,000)[2]	Unadjusted rates among persons vaccinated with 2 doses (per 100,000)[2]	Unadjusted rates among persons not vaccinated (per 100,000)[2]
Under 18	586.2	3,149.6	0.7	5.3	0.0	0.0	0.0	0.0
18-29	532.9	674.0	1.3	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
30-39	1,071.8	817.7	3.4	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
40-49	1,936.2	834.9	7.1	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
50-59	1,248.7	586.1	8.9	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
60-69	83[illegible]	391.2	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
70-79	635.[illegible]	312.2	29.8	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
≥80	432.5	333.8	56.8	120.8	44.9	110.0	55.5	128.5

+2,885

It's the **week of the turning point**: summing all the age columns, the cases among vaccinated with 2 doses exceed those of the not vaccinated!

Tot. cases: **7,280** 7,100
(cases in vaccinated **+180**, i.e. **+2.5%**)

The trend continues consistently in the subsequent weeks, and…

Week 2 - 2022

Table 12. Unadjusted rates of COVID-19 infection, hospitalisation and death in vaccinated and unvaccinated populations.
Please note that the following table should be read in conjunction with pages 35 to 38 of this report, and the footnotes provided on page 43.

	Cases reported by specimen date between week 50 2021 and week 1 2022		Cases presenting to emergency care (within 28 days of a positive test) resulting in overnight inpatient admission, by specimen date between week 50 2021 and week 1 2022		Death within 28 days of positive COVID-19 test by date of death between week 50 2021 and week 1 2022	
	[see information on population bases and unadjusted rates in footnotes 1 and 2 below this table]					
	Unadjusted rates among persons vaccinated with 2 doses (per 100,000)[1,2]	Unadjusted rates among persons not vaccinated (per 100,000)[1,2]	Unadjusted rates among persons vaccinated with 2 doses (per 100,000)[2]	Unadjusted rates among persons not vaccinated (per 100,000)[2]	Unadjusted rates among persons vaccinated with 2 doses (per 100,000)[2]	Unadjusted rates among persons not vaccinated (per 100,000)[2]
Under 18	2,356.6	3,376.1	1.8	10.9	0.0	0.1
18 to 29	8,926.0	4,058.9	10.5	16.9	0.1	0.5
30 to 39	7,618.8	3,268.8	10.2	21.1	0.4	1.3
40 to 49	6,330.1	2,585.9	11.3	32.9	0.6	4.2
50 to 59	4,796.2	2,117.0	13.6	61.5	1.8	11.6
60 to 69	3,099.9	1,477.9	17.8	100.4	4.9	34.0
70 to 79	1,926.2	1,059.6	32.1	170.5	10.1	81.3
80 or over	1,657.7	1,262.9	88.7	330.8	42.4	246.7

+18,524

Tot. cases: **36,712** 19.207
(cases in vaccinated **+17,504**, i.e. **+91%**)

The vaccinated show **many more** infections than not vaccinated.

The excess of total cases in the vaccinated column started from week 43/2021 and it exploded in a few months!

But…

Week 3 - 2022

COVID-19 vaccine surveillance report - week 3

Table 12. Unadjusted rates of COVID-19 infection, hospitalisation and death in vaccinated and unvaccinated populations.
Please note that the following table should be read in conjunction with pages 30 to 33 of this report, and the footnotes provided on page 38.

	Cases reported by specimen date between week 51 2021 (w/e 26/12/21) and week 02 2022 (w/e 16/01/22)		Cases presenting to emergency care (within 28 days of a positive test) resulting in overnight inpatient admission, by specimen date between week 51 2021 (w/e 26/12/21) and week 02 2022 (w/e 16/01/22)		Death within 28 days of positive COVID-19 test by date of death between week 51 2021 (w/e 26/12/21) and week 02 2022 (w/e 16/01/22)	
	[see information on population bases and unadjusted rates in footnotes 1 and 2 below this table]					
	Unadjusted rates among persons vaccinated with at least 3 doses (per 100,000)	Unadjusted rates among persons not vaccinated (per 100,000)[1,2]	Unadjusted rates among persons vaccinated with at least 3 doses (per 100,000)	Unadjusted rates among persons not vaccinated (per 100,000)[2]	Unadjusted rates among persons vaccinated with at least 3 doses (per 100,000)	Unadjusted rates among persons not vaccinated (per 100,000)[2]
Under 18	2,295.7	3,990.1	10.0	12.7	0.0	0.1
18-29	3,460.5	3,853.3	4.3	17.0	0.0	0.5
30-39	3,857.1	3,251.7	5.2	20.6	0.1	1.4
40-49	4,012.4	2,573.9	5.5	28.3	0.2	3.2
50-59	3,995.9	2,133.3	8.2	52.7	0.5	12.3
60-69	3,070.0	1,499.8	12.8	92.7	2.1	37.2
70-79	2,062.8	1,129.7	28.9	180.1	5.9	90.4
≥80	1,842.6	1,374.8	85.5	347.2	33.2	293.3

+6,524

Casi tot.: **24,597** 19.807
(casi in **tri**vaccinati **+4,790**, cioè **+24%**)

From week 3, the UK Security Agency decided to **compare** with unvaccinated **only subjects with 3 doses** (or more). Despite this change, the **vaccinated persons continue to have more infections** than unvaccinated.

Week 13 - 2022

Table 14. Unadjusted rates of COVID-19 infection, hospitalisation and death in vaccinated and unvaccinated populations.
Please note that the following table should be read in conjunction with pages 38 to 41 of this report, and the footnotes provided on page 46.

	Cases reported by specimen date between week 9 2022 (w/e 6 March 2022) and week 12 2022 (w/e 27 March 2022)		Cases presenting to emergency care (within 28 days of a positive test) resulting in overnight inpatient admission, by specimen date between week 9 2022 (w/e 6 March 2022) and week 12 2022 (w/e 27 March 2022)		Death within 28 days of positive COVID-19 test by date of death between week 9 2022 (w/e 6 March 2022) and week 12 2022 (w/e 27 March 2022)	
	[see information on population bases and unadjusted rates in footnotes 1 and 2 below this table					
	Unadjusted rates among persons vaccinated with at least 3 doses (per 100,000)	Unadjusted rates among persons not vaccinated (per 100,000)[1,2]	Unadjusted rates among persons vaccinated with at least 3 doses (per 100,000)	Unadjusted rates among persons not vaccinated (per 100,000)[2]	Unadjusted rates among persons vaccinated with at least 3 doses (per 100,000)	Unadjusted rates among persons not vaccinated (per 100,000)[2]
Under 18	1,454.0	1,711.7	3.1	9.6	0.0	0.0
18 to 29	3,118.8	941.6	5.4	8.2	0.1	0.0
30 to 39	4,324.7	1,085.6	6.8	7.4	0.2	0.3
40 to 49	3,957.8	955.3	6.0	7.7	0.2	0.3
50 to 59	3,303.4	779.8	9.0	12.9	0.5	1.6
60 to 69	2,814.9	572.8	14.3	22.1	1.5	5.9
70 to 79	2,161.5	532.1	36.6	58.8	6.8	20.2
80 or over	2,023.7	775.6	117.9	123.5	44.6	87.4

Cases+ 3.15 times more!

Casi tot.: **21,705** 7.355

(casi in vaccinati con almeno 3 dosi **+15,804**, cioè **+215%** vs non vaccinati !)

The positive cases among vaccinated (vs not vaccinated) have continued to grow, with no slowdowns, from 23 weeks. It is really clear that even with ≥3 doses the **vaccinated people are more likely to become infected in the medium term**.

The NEW ENGLAND JOURNAL of MEDICINE

Does the 4th dose restore protection? This is the answer!

ORIGINAL ARTICLE

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel

Yinon M. Bar-On, M.Sc., Yair Goldberg, Ph.D., Micha Mandel, Ph.D., ...

This article was published on April 5, 2022, at NEJM.org.



Figure 2. Adjusted Rate Ratios for Confirmed Infection and Severe Illness.

In less than 2 months one returns to the starting square in the game of the goose



Tempo (mesi) da 14 giorni dopo la 2ª dose (considerata la "protezione completa")

In 4 months the Pfizer vaccine **mean protection against Omicron** is nearly **zero** (**and its trend is to get worse!**)

Accordingly, if we vaccinate children, they will infect the grandparents after a few months, or should be boostered for life**!**

Moreover, is it logical to demand an antigenic test every two days to give a guarantee comparable to a vaccination?!?

No! Even a weekly test would be better than zero guarantee!

Efficacia dei vaccini Pfizer e Moderna contro l'infezione da SARS-CoV-2 con variante Omicron (adattata da *Hansen*[1] *et al., medRxiv preprint 2021.12.20.21267966*) **Danmark**

[1] *Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, DK*

The NEW ENGLAND JOURNAL of MEDICINE

CORRESPONDENCE

letter was published on January 26, 2022, at NEJM.org.

Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar

Laith J. Abu-Raddad, Ph.D.
Hiam Chemaitelly, Ph.D.





Among the vaccinated, asymptomatic infections increase first

Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant

	Stime					
Rapporto di incidenza $\frac{\text{tasso non vaccinati}}{\text{tasso vaccinati}}$	2,7	2,0	1,4	1,1	0,9	0,7
Efficacia del vaccino $1-\left(\frac{1}{\text{rapp. di incidenza}}\right)$	65%	51%	29%	12%	-10%	-41%



days!

Preprint means that the study could change after a peer review

It means that after 1.5 months from the primary cycle the child could get infected (and infect me) even more?!



Incidence rate ratios, comparing cases for unvaccinated versus children newly fully vaccinated 5-11 years (Dec 13, 2021-Jan 2, 2022), by time since vaccination

(adattata da *Dorabawila et al., medRxiv preprint 2022.02.25.22271454*)

Percentage of COVID-19 cases in vaccinated vs unvaccinated Italian children 5-11 years (processing based on ISS data – Report of March 16, 2022)

Epidemia COVID-19 (iss.it)



* In March the difference in cases+ between full-cycle vaccinated and unvaccinated was statistically highly significant favoring vaccinated

RR = 0.91

P < 0.0001

Percentage of COVID-19 cases in vaccinated vs unvaccinated Italian children 5-11 years (processing based on ISS data – Report of March 23, 2022)

Epidemia COVID-19 (iss.it)





* but a week later the difference in cases+ between full-cycle vaccinated and unvaccinated was statistically highly significant favoring unvaccinated

RR = 1.100

P < 0.0001

Percentage of COVID-19 cases in vaccinated vs unvaccinated Italian children 5-11 years (processing based on ISS data – Report of March 30, 2022)

Epidemia COVID-19 (iss.it)





* … a week later the difference in cases+ between full-cycle vaccinated and unvaccinated, always statistically highly significant, favors even more unvaccinated

RR = 1.1911

P < 0.0001

Percentage of COVID-19 cases in vaccinated vs unvaccinated Italian children 5-11 years (processing based on ISS data – Report of April 6, 2022)

Epidemia COVID-19 (iss.it)





* the difference in cases+ between full-cycle vaccinated and unvaccinated is statistically highly significant favoring unvaccinated

RR = 1.2158

$P < 0.0001$

Percentage of COVID-19 cases in vaccinated vs unvaccinated Italian children 5-11 years (processing based on ISS data – Report of April 13, 2022)

Epidemia COVID-19 (iss.it)





* the difference in cases+ between full-cycle vaccinated and unvaccinated

is statistically highly significant favoring unvaccinated

RR = 1.2335

P < 0.0001

NNH [Number Needed (to vaccinate) to Harm, i.e. to have 1 more infection]=

= from 81 to 88

How long is the Green Pass issued to children valid?

Once they receive the second dose, they will get a nine-month certificate, just like adults.



Conclusion

If the EU Digital COVID-19 Certificate is aimed to protect the European Community from SARS-CoV-2 infections

it does not have the claimed scientific support (and may even be hazardous in the medium term for public health), therefore it could be safely dismissed, (with several effective alternatives)

THANK YOU FOR YOUR ATTENTION!